Clinical Trial Detail

NCT ID NCT02268175
Title Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate adenocarcinoma

Therapies

Enzalutamide

Abiraterone

Prednisone

Leuprolide

Age Groups: adult

No variant requirements are available.